Red Light Holland Receives Initial Third-Party Psilocybin Testing Results via FDA-Compliant, DEA-Registered Partner, Irvine Labs
Red Light Holland (OTCQB:TRUFF) has received initial third-party testing results from Irvine Labs, validating the psilocybin potency and process compatibility of its naturally occurring psilocybin products for potential medical grade manufacturing applications.
Following the first global psilocybin shipment from the Netherlands to Irvine Labs' FDA-compliant and DEA-registered facility in California in July 2025, the company is now advancing the development of proprietary dehydration and packaging processes to extend shelf life while maintaining product integrity. The partnership aims to create standardized psilocybin products for emerging therapeutic markets, government-funded pilot programs, and clinical trials in the United States.
Red Light Holland (OTCQB:TRUFF) ha ricevuto i primi risultati dei test di terze parti da Irvine Labs, che confermano la potenza della psilocibina e la compatibilità dei suoi prodotti naturali a base di psilocibina con i processi necessari per la produzione potenzialmente di qualità medica.
Dopo la prima spedizione globale di psilocibina dai Paesi Bassi all'impianto californiano conforme alla FDA e registrato presso la DEA di Irvine Labs, avvenuta a luglio 2025, l'azienda sta ora sviluppando processi proprietari di essiccazione e confezionamento per prolungare la shelf life preservando l'integrità del prodotto. La collaborazione punta a creare prodotti di psilocibina standardizzati per i mercati terapeutici emergenti, per programmi pilota finanziati dallo Stato e per studi clinici negli Stati Uniti.
Red Light Holland (OTCQB:TRUFF) ha recibido los primeros resultados de pruebas de terceros de Irvine Labs, que validan la potencia de la psilocibina y la compatibilidad de proceso de sus productos naturales con psilocibina para posibles aplicaciones de fabricación de calidad médica.
Tras el primer envío global de psilocibina desde los Países Bajos al centro de Irvine Labs en California, conforme a la FDA y registrado en la DEA, en julio de 2025, la compañía avanza ahora en el desarrollo de procesos propietarios de deshidratación y envasado para ampliar la vida útil manteniendo la integridad del producto. La asociación busca crear productos estandarizados de psilocibina para los emergentes mercados terapéuticos, programas piloto financiados por el gobierno y ensayos clínicos en Estados Unidos.
Red Light Holland (OTCQB:TRUFF)는 Irvine Labs의 초기 제3자 검사 결과를 받았으며, 자사의 천연 발생 실로시빈 제품이 의학용 등급 제조에 적용될 수 있도록 실로시빈 함량과 공정 적합성이 검증되었습니다.
2025년 7월 네덜란드에서 FDA 준수·DEA 등록을 마친 Irvine Labs의 캘리포니아 시설로 최초 글로벌 실로시빈 수송이 이루어진 이후, 회사는 제품의 무결성을 유지하면서 보관 기한을 연장하기 위한 독자적 건조 및 포장 공정 개발을 추진하고 있습니다. 이 파트너십은 신흥 치료 시장, 정부 지원 파일럿 프로그램 및 미국 내 임상시험을 위한 표준화된 실로시빈 제품을 만드는 것을 목표로 합니다.
Red Light Holland (OTCQB:TRUFF) a reçu les premiers résultats de tests effectués par un tiers, réalisés par Irvine Labs, confirmant la puissance en psilocybine et la compatibilité des processus de ses produits naturels contenant de la psilocybine pour d'éventuelles applications de fabrication de qualité médicale.
Suite au premier envoi mondial de psilocybine des Pays-Bas vers l'installation californienne d'Irvine Labs, conforme à la FDA et enregistrée auprès de la DEA, en juillet 2025, la société développe désormais des procédés propriétaires de déshydratation et d'emballage pour prolonger la durée de conservation tout en préservant l'intégrité du produit. Ce partenariat vise à créer des produits de psilocybine standardisés pour les marchés thérapeutiques émergents, les programmes pilotes financés par l'État et les essais cliniques aux États-Unis.
Red Light Holland (OTCQB:TRUFF) hat erste Drittprüfungs-Ergebnisse von Irvine Labs erhalten, die die Psilocybin-Potenz und die Prozesskompatibilität seiner natürlich vorkommenden Psilocybin-Produkte für potenzielle medizinische Herstellungsanwendungen bestätigen.
Nach der ersten weltweiten Psilocybin-Sendung aus den Niederlanden an die FDA-konforme und bei der DEA registrierte Einrichtung von Irvine Labs in Kalifornien im Juli 2025, treibt das Unternehmen nun die Entwicklung proprietärer Dehydrations- und Verpackungsprozesse voran, um die Haltbarkeit zu verlängern und gleichzeitig die Produktintegrität zu bewahren. Die Partnerschaft zielt darauf ab, standardisierte Psilocybin-Produkte für aufkommende therapeutische Märkte, staatlich geförderte Pilotprogramme und klinische Studien in den USA zu schaffen.
- Successful validation of psilocybin potency and process compatibility for medical grade applications
- Development of proprietary preservation processes to extend product shelf life
- Established partnership with FDA-compliant and DEA-registered facility
- Access to Irvine Labs' 2025 DEA quota allocation for future imports
- Still in early testing and development phase
- Regulatory approval for medical applications not yet secured
- Limited to specific markets due to current legal restrictions
- Initial testing results confirm psilocybin potency and process validation for potential medical grade manufacturing applications
- Irvine Labs progresses development of proprietary dehydration and packaging processes while preparing for next scheduled import
Toronto, Ontario--(Newsfile Corp. - August 18, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, as well as a premium brand of psilocybin truffles in the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce that it has received initial testing results from its research and development partner, Irvine Labs Inc. ("Irvine Labs"), confirming the psilocybin quantity and process compatibility from the Company's naturally occurring psilocybin products for potential medical grade manufacturing applications.
Following the successful delivery of the first global shipment of psilocybin from Red Light Holland's Netherlands facility to the FDA-compliant and DEA-registered Irvine Labs facility in California in July, initial potency testing via third-party laboratory has now been completed. The results confirm that Red Light Holland's naturally derived psilocybin truffles are compatible with the manufacturing processes being developed for potential medical grade applications.
Irvine Labs is now advancing the development of proprietary dehydration and packaging processes designed to significantly extend shelf life while maintaining product integrity. Additionally, preparations are underway for the next scheduled import under Irvine Labs' existing 2025 DEA quota allocation.
"We are pleased to receive these initial testing results confirming that our naturally derived psilocybin products are compatible with the manufacturing processes being developed," said Todd Shapiro, CEO and Director of Red Light Holland. "This validation represents progress in our partnership with Irvine Labs and moves us forward in developing standardized psilocybin products for emerging therapeutic markets."
Shaun Land, President of Irvine Labs, added, "The initial testing results validate our process development approach with Red Light Holland's psilocybin materials. We are now focused on optimizing our proprietary preservation processes and preparing for expanded operations. These results confirm our ability to work with Red Light Holland's materials in developing products for potential medical grade applications, which supports our goal of advancing government-funded pilot programs and clinical trials."
The Company and Irvine Labs continue their collaborative research and development efforts aimed at creating a commercialized and standardized psilocybin product that can be legally distributed to emerging markets and utilized in government-funded pilot programs and clinical trials within the United States.
About Irvine Labs
Irvine Labs was established in 1997. Since 2013, Irvine Labs has had a significant investment in medical research and development through its Pharmaceutical Biotechnology Division with a focus on natural medicines, including cannabis, cannabinoids, psilocybin, herbs and other sources of natural medicines. Irvine Labs is licensed for Prescription and Over-the-Counter (OTC) drug manufacturing by the California Department of Public Health (CDPH). Irvine Labs is a DEA Schedule 1 Bulk drug manufacturer, importer and exporter (including marijuana, THC, extracts, psilocybin, psilocin, DET, DMT, LSD, Peyote and Mescaline, and Schedule 1-5 testing lab.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
Forward-Looking Statements and Cautionary Note
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.
The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and Irvine lab's development of the Company's psilocybin; the Company and the Company's partners to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the expectations with respect to the Company's development work following the successful testing results of the psilocybin materials delivered to Irvine Labs; the Company's plans for continued development of dehydration and packaging processes by Irvine Labs; the Company's plans for future scheduled imports of psilocybin materials under Irvine Labs' existing 2025 DEA quota; the suitability of the Company's psilocybin materials for medical grade manufacturing applications; the Company's continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs Inc. and the research project to develop a process for the commercial manufacture of microdosing capsules derived from the Company's psilocybin truffles that could be used for medical grade applications; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving further important insights from naturally occurring psilocybin truffles; the Company's ability to extract and expand access to psilocybin products; the Company's ability to sell their product in future legal markets, as currently the company has no control on timing or policy change on future emerging markets, and the Company's ability to scalable production of high-quality, and approved microdosing capsules with extended shelf life via Irvine Labs ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the United States or around the world.
Forward-Looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' abilities, including Irvine Labs to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's ability to realize its plans for continued psilocybin development work following the successful testing results of the materials delivered to Irvine Labs; the Company's ability to successfully continue development of dehydration and packaging processes through Irvine Labs; the Company's ability to mexecute future scheduled imports of psilocybin materials under Irvine Labs' existing 2025 DEA quota; the continued suitability of the Company's psilocybin materials for medical grade manufacturing applications; the Company's ability for its continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's ability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs and their research project to develop a process for the commercial manufacture of natural-source microdosing capsules derived from the Company's psilocybin truffles that could be used for medical grade applications; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the ability to extract and expand access to psilocybin products; and the Company's ability to have scalable production of high-quality, microdosing capsules with extended shelf life for Global Distribution and The Company's ability to continue shipping products to the United States and eventually the Company's ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the US or around the world.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' inabilities, including Irvine Labs, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's inability to realize upon its plans for continued psilocybin development despite the successful testing results; potential issues with ongoing development of dehydration and packaging processes; potential delays or complications with future scheduled imports under the existing DEA quota; changes in the suitability assessment of psilocybin materials for medical grade manufacturing applications; potential issues with future development work; the Company's inability to maintain its commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's inability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs; and The Company's ability to expand and extract access to psilocybin products.
The Company cannot make medical claims and is purely in a R&D phase with its partners Irvine Labs Inc.
Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262845
FAQ
What were the results of Red Light Holland's (TRUFF) psilocybin testing at Irvine Labs?
When did Red Light Holland complete its first psilocybin shipment to Irvine Labs?
What is the purpose of Red Light Holland's partnership with Irvine Labs?
What processes is Irvine Labs developing for Red Light Holland's psilocybin products?
What certifications does Irvine Labs have for handling psilocybin?
